Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
07 August 2024 - 4:00PM
UK Regulatory
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) --
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, announced today the appointment of Dr. Adrian Kilcoyne,
M.D., MPH, MBA as its Chief Medical Officer, effective
immediately.
“We’re thrilled to welcome Dr. Kilcoyne to
Cellectis. He is a strategic, forward-thinking drug developer who
is passionate about delivering life-saving therapies to patients.
His clinical vision and proven leadership, as well as his extensive
experience, will strengthen our clinical development efforts as we
advance our product pipeline of next-generation CAR T-cell
therapies,” said André Choulika, Ph.D., Chief Executive Officer at
Cellectis.
Before joining Cellectis, Dr. Kilcoyne was Chief
Medical Officer and Head of Research and Development at
Celularity, advancing their oncology allogeneic CAR-T and NK Cell
therapy programs. Prior to this, he was Chief Medical Officer at
Humanigen. He has held numerous Oncology leadership roles across
Research and Development, Medical Affairs, Commercial, Health
Economic Outcome Research and Evidence Generation in both
large pharmaceutical and biotechnology companies such as
AstraZeneca and Celgene. Dr. Kilcoyne graduated from Trinity
College, Dublin Medical School. He initially trained in
Gynecological Oncology at the Hammersmith Hospital in London and
subsequently in Public Health Medicine at Oxford during which time
he completed a Master’s in Public Health. Dr. Kilcoyne then trained
in pharmaceutical medicine and completed his MBA.
“I am excited to join Cellectis at this pivotal
time for the company as it is poised to deliver on its mission to
provide transformative UCART therapies to patients with significant
unmet medical need,” said Dr. Adrian Kilcoyne. “I believe that
Cellectis’ world-class capabilities in gene editing and cell
therapy manufacturing, promising pipeline and experienced
leadership team will enable us to accelerate our current
clinical pipeline and drive future innovation as we
strive to deliver first-in-class and best-in-class allogeneic cell
and gene therapies.”
Dr. Mark Frattini departs Cellectis effective
immediately to pursue other opportunities. We thank Dr. Frattini
for his contributions and wish him well in his new endeavors.
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
24 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“believe,” “poised to”, and “will,” or the negative of these and
similar expressions. These forward-looking statements, which are
based on our management’s current expectations and assumptions and
on information currently available to management. Forward-looking
statements include statements about the advancement of development
of our product candidates' pipeline, and the potential of our
product candidate. These forward-looking statements are made in
light of information currently available to us and are subject to
numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development. With respect to our cash runway, our operating plans,
including product development plans, may change as a result of
various factors, including factors currently unknown to us.
Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2023 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33
(0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the
CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Interim Chief Financial Officer,
+1 (347) 809 5980, investors@cellectis.com
- 20240805_PR_20240807_ENGLISH revAS
Cellectis Nom Eo 05 (TG:ZVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellectis Nom Eo 05 (TG:ZVA)
Historical Stock Chart
From Sep 2023 to Sep 2024